NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Gaudium IVF Reports Q2 PAT of ₹8.20 Cr; Revises 6 Locations for ₹50 Cr IPO Expansion
Gaudium IVF reported Q2 FY27 standalone revenue from operations of ₹28.06 crore (up 105% QoQ vs ₹13.68 crore in Q1 FY27, and up 22.3% YoY vs ₹22.95 crore in Q2 FY26). Standalone profit after tax for the quarter stood at ₹8.20 crore compared to ₹1.66 crore in Q1 FY27 and ₹9.03 crore in Q2 FY26. Concurrently, the Board approved a variation in IPO objects to change 6 of the 19 planned center locations and extend the timeline to FY2029, keeping the earmarked capex unchanged at ₹50.00 crore. As of September 30, 2026, the company has utilized ₹13.48 crore of the ₹50.00 crore earmarked for new centers.
உச்சம் நம்பிக்கை
என்ன மாறியதுGaudium IVF approved its Q2 FY27 results and proposed substituting 6 target cities for its 19-center expansion plan, aiming for completion by FY2029.
ஏன் இது முக்கியம்The change in target locations reflects revised expansion strategy into high-potential Tier-2 markets without changing the ₹50 crore budget, while Q2 operational metrics staged a sharp rebound from Q1 FY27.
Q2 Standalone Revenue: ₹2,805.68 லட்சம்Q2 Standalone PAT: ₹819.97 லட்சம்Capex for 19 Centres: ₹5,000.00 லட்சம்IPO Capex utilized till Sep 2026: ₹1,348.48 லட்சம்IPO Capex vs TTM Revenue: ~47.2%
📅 குறுகிய காலம்Sequential operational recovery in revenue and profitability is likely to support sentiment, though investors will eye the upcoming postal ballot approval.
📈 நீண்ட காலம்The addition of 19 new centers by FY2029 represents a significant network expansion that could drive multi-year revenue growth if clinic ramp-ups and patient footfalls meet expectations.
⚠ அபாய எச்சரிக்கைகள்
Execution delays in rolling out new centers across modified cities by FY2029
Shareholder approval risk via postal ballot for variation in IPO objects
👀 கவனிக்க வேண்டியவை
Track shareholder voting via Postal Ballot for the proposed variation in IPO objects, and monitor execution milestones for the planned rollout of 10 new centers in FY2027.
Gaudium IVF Q2 FY27 Revenue Up 17.9% YoY to ₹37.4 Cr; PAT Flat at ₹9.4 Cr Amid Expansion
Gaudium IVF reported a 17.9% YoY increase in Q2 FY27 revenue to ₹37.4 crore, driven by mature hub volumes and initial contributions from its new South Extension centre. EBITDA contracted slightly by 2.1% YoY to ₹13.5 crore, causing margins to drop 737 bps to 36.0% due to initial fixed overheads and rollout costs for two new hubs. Net profit remained flat at ₹9.4 crore (up 0.4% YoY) with a PAT margin of 25.2%. For H1 FY27, revenue reached ₹56.8 crore (up 14.7% YoY) while PAT declined 10.5% YoY to ₹11.2 crore as the company executes its planned 19-centre expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுGaudium IVF released its Q2 and H1 FY27 financial results alongside operational updates on opening two new hubs in South Extension and Gurgaon.
ஏன் இது முக்கியம்Topline growth remains strong, but margins are facing near-term dilution from pre-operative and upfront fixed costs associated with rapid network expansion.
📅 குறுகிய காலம்Margins are expected to remain under pressure in the coming quarters as additional centres under the 19-hub expansion are commissioned ahead of peak patient volumes.
📈 நீண்ட காலம்As newly launched centres ramp up to breakeven within 3-6 months, operating leverage should restore consolidated EBITDA margins toward historical levels above 35-40%.
⚠ அபாய எச்சரிக்கைகள்
Margin dilution risk from high upfront fixed costs of new hubs
Execution risk on achieving breakeven timelines for the remaining 17 centres planned
👀 கவனிக்க வேண்டியவை
Track the breakeven progress of the two newly operational hubs (targeted within 3-6 months) and the pace of further rollout under the planned 19-centre expansion.
Gaudium IVF Commences Commercial Operations at New IVF Centre in Gurgaon
Gaudium IVF and Women Health Limited has commenced commercial operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026. This launch is in line with the IPO objects stated in its Prospectus dated February 25, 2026. The centre is equipped with IVF and healthcare infrastructure, including its proprietary Gaudium Signature Lab. The addition expands the company's footprint beyond its Jun 2026 revenue base of Rs 19.38 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுGaudium IVF officially operationalized its new Gurgaon IVF Centre/Hub on September 24, 2026.
ஏன் இது முக்கியம்Delivers on the capital deployment outlined during its IPO, augmenting clinic network capacity to support revenue growth in the NCR region.
Date of Commencement: செப்டம்பர் 24, 2026Prospectus Date: பிப்ரவரி 25, 2026Jun 2026 Quarterly Revenue: Rs 19.38 கோடி
📅 குறுகிய காலம்Positive sentiment from meeting stated IPO milestones; initial gestation and ramp-up may briefly increase operating expenses.
📈 நீண்ட காலம்Supports market share consolidation in premium fertility care within North India, expanding addressable patient volumes.
⚠ அபாய எச்சரிக்கைகள்
Gestation period and ramp-up time before achieving optimal clinic utilization
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and operational efficiency metrics for the Gurgaon facility in upcoming quarterly results, alongside utilization rates and revenue contribution.
Gaudium IVF reported Q1 FY27 revenue growth of 9.1% YoY to ₹19.4 crore, with EBITDA of ₹2.4 crore and PAT of ₹1.8 crore, reflecting pre-investments for expansion. Management reiterated FY27 revenue growth guidance of 30% YoY. The company is executing its 19-centre IPO rollout plan, aiming for 10 new hubs in FY27 (South Extension operational, Gurgaon and Nagpur opening shortly) alongside international spokes in Paris, Nigeria, and Sydney.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q1 FY27 earnings conference call held on August 14, 2026.
ஏன் இது முக்கியம்Provides detailed management commentary on the 30% FY27 growth target, margin trajectory, AI clinical tool integration, and network expansion status across India and international spokes.
📅 குறுகிய காலம்Focus will remain on the execution and footfall traction of recently launched hubs (South Delhi, Gurgaon, Nagpur).
📈 நீண்ட காலம்Structural tailwinds from the ART & Surrogacy Act consolidation, combined with proprietary AI signature labs and Tier-2 hub-and-spoke expansion, support multi-year volume growth.
⚠ அபாய எச்சரிக்கைகள்
Execution delays in opening new hubs
Near-term margin drag from upfront hub setup costs prior to breakeven
👀 கவனிக்க வேண்டியவை
Track operational launch timelines and ramp-up metrics of upcoming hubs in Gurgaon and Nagpur, and monitor margin expansion in subsequent quarters as new hubs mature.
Gaudium IVF issued a revised Q1 FY27 investor presentation to correct EBITDA figures and disclose a one-time marketing expense of Rs 2.53 crore related to its AI tools, SID and ERICA. The consolidated adjusted EBITDA is now reported at Rs 5.33 crore with a 27.49% margin, while standalone adjusted EBITDA stands at Rs 5.08 crore (37.12% margin). The company reported Q1 FY27 revenue of Rs 19.38 crore, a decline from the Rs 24.51 crore reported in Dec 2025. Management highlighted an aggressive expansion plan to add 10 new hubs by FY29, starting with two in FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company corrected its previously filed investor presentation to include a specific one-time marketing expense and revised its Adjusted EBITDA margin calculations.
ஏன் இது முக்கியம்The disclosure clarifies that the margin pressure in Q1 FY27 was largely due to a non-recurring marketing investment (representing ~13% of quarterly revenue), providing a clearer picture of underlying operational profitability.
📅 குறுகிய காலம்The clarification of one-time costs may support sentiment as it explains the sequential dip in profitability from the Dec 2025 quarter.
📈 நீண்ட காலம்The company is positioning itself as an AI-driven IVF platform with a plan to more than double its hub count (from 8 to 19) by FY29, targeting a highly underpenetrated market.
⚠ அபாய எச்சரிக்கைகள்
High marketing-to-revenue ratio
Execution risk associated with rapid hub expansion
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the 10-hub expansion plan and whether the one-time marketing spend of Rs 2.53 crore translates into higher patient footfalls in subsequent quarters.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Gaudium IVF reported Q1 FY27 revenue of Rs 19.38 cr, showing a moderation compared to the Dec 2025 quarter (Rs 24.51 cr) due to expansion-related costs. The company currently operates 8 hubs and 28 spokes across 9 states, with an average revenue per patient of Rs 3.5 lakhs. Profitability was impacted by investments in new hubs in Gurgaon and Nagpur and AI-led embryology tools, resulting in an adjusted EBITDA margin of 27.49%. Despite short-term margin pressure, the company maintains a high first-attempt success rate of 62%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a private entity to a listed player, now disclosing detailed operational metrics including ARPP and AI-driven success rate improvements.
ஏன் இது முக்கியம்The IVF industry in India is highly underpenetrated (<2%), and Gaudium is positioning itself as an organized, AI-enabled platform to capture the projected 13.1% industry CAGR.
📅 குறுகிய காலம்The stock may see some pressure or sideways movement as the market digests the sequential revenue decline and the impact of expansion costs on current margins.
📈 நீண்ட காலம்The long-term outlook remains tied to the company's ability to scale its hub-and-spoke model and maintain clinical success rates above the industry average in a growing market.
⚠ அபாய எச்சரிக்கைகள்
Expansion-related cost overruns
High concentration of revenue from IVF treatments
Regulatory risks associated with the ART (Regulation) Act
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline and ramp-up of the under-construction centers in Gurgaon and Nagpur to see if they offset current expansion costs. Additionally, watch for improvements in success rates and patient conversion following the integration of AI tools SiD and ERICA.
9.1% Revenue Growth in Q1FY27; EBITDA Drops 53% on Expansion Costs; ₹15 Cr Lucknow Project Approved
Gaudium IVF reported Q1 FY27 revenue of ₹19.4 Cr, a 9.1% YoY increase, though profitability was significantly impacted by expansion activities. EBITDA fell 53% YoY to ₹2.4 Cr as margins compressed from 29% to 12.5% due to pre-operational costs for new hubs and clinical hiring. The company is executing a 19-centre expansion roadmap, with the South Extension hub already operational and a new ₹15 Cr hospital approved in Lucknow. Management indicates that excluding one-off expansion costs, EBITDA margins would have remained steady at approximately 27.6%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into an aggressive expansion phase, sacrificing short-term margins (down 1651 bps) to fund a 19-centre rollout and entry into the Uttar Pradesh market.
ஏன் இது முக்கியம்The IVF market is highly fragmented; Gaudium's ability to scale from 8 hubs to 27 hubs while maintaining its 62% success rate will determine its long-term valuation and market leadership.
📅 குறுகிய காலம்The stock may face pressure due to the sharp decline in EBITDA and PAT, as the market digests the high cost of expansion versus the modest 9% revenue growth.
📈 நீண்ட காலம்If the company successfully executes its 19-centre expansion and restores margins to the 27% level seen in mature hubs, it could represent significant structural growth.
⚠ அபாய எச்சரிக்கைகள்
Margin compression from front-loaded expansion costs
Execution risk in rolling out 10 hubs within a single financial year
👀 கவனிக்க வேண்டியவை
Monitor the revenue ramp-up and margin recovery in the upcoming quarters as the 10 planned hubs for FY27 become operational and move toward steady-state utilization.
Gaudium IVF Approves Q1 FY27 Results; Appoints Secretarial Auditor for 5-Year Term
Gaudium IVF and Women Health Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during its board meeting on August 13, 2026. The company re-appointed Ram Rattan & Associates as Internal Auditor for FY 2026-27 and proposed Suresh Nainwal & Company as Secretarial Auditor for a five-year term. Additionally, the board reviewed the statement of deviation or variation under Regulation 32 regarding the utilization of fundraise proceeds. These actions represent standard quarterly compliance and governance updates.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized its financial reporting for the first quarter of FY27 and updated its audit oversight team.
ஏன் இது முக்கியம்Regular financial reporting and the appointment of long-term auditors are essential for maintaining corporate governance and transparency for a listed entity.
Quarter ended: ஜூன் 30, 2026Secretarial Auditor Term: 5 consecutive yearsInternal Auditor Tenure: FY 2026-27Board Meeting Date: ஆகஸ்ட் 13, 2026
📅 குறுகிய காலம்The stock may react to the specific earnings figures contained in the Q1 results over the coming days.
📈 நீண்ட காலம்Limited; these are routine administrative and financial reporting activities that support long-term governance.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q1 FY27 financial statements to assess revenue growth and margin trends. Monitor the upcoming Annual General Meeting for the formal approval of the new secretarial auditor.
Gaudium IVF and Women Health Limited reported a standalone revenue of ₹13.68 cr for Q1 FY27, a significant sequential decline from ₹22.17 cr in Q4 FY26. The company has successfully utilized ₹18.07 cr of its IPO proceeds to become debt-free as of June 30, 2026. Capital expenditure for new IVF centers is in the early stages, with only ₹1.03 cr spent out of the ₹50 cr allocated. Additionally, the board approved the appointment of M/s. Suresh Nainwal & Company as Secretarial Auditors for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first full quarter results post-listing, confirmed its debt-free status, and appointed new secretarial auditors for a 5-year term.
ஏன் இது முக்கியம்While the company is now debt-free, the sharp sequential drop in revenue and profit suggests volatility in quarterly performance; the slow start to capex deployment is a key factor for long-term growth tracking.
Q1 FY27 Revenue: ₹13.68 கோடிQ1 FY27 PAT: ₹1.66 கோடிIPO Fresh Issue Proceeds: ₹90.00 கோடிDebt Repayment Utilized: ₹18.07 கோடிNew IVF Center Capex (Allocated): ₹50.00 கோடிNew IVF Center Capex (Spent): ₹1.03 கோடி
📅 குறுகிய காலம்The market may react to the sequential decline in profitability and revenue compared to the March 2026 quarter.
📈 நீண்ட காலம்Long-term value creation depends on the successful rollout of new IVF centers using the remaining ₹48.97 cr of allocated IPO funds.
⚠ அபாய எச்சரிக்கைகள்
Significant sequential decline in net profit
Slow utilization of expansion capital
👀 கவனிக்க வேண்டியவை
Investors should monitor the pace of the ₹50 cr capex deployment for new IVF centers, as the current utilization is minimal and future growth depends on this expansion.
Gaudium IVF reported standalone revenue of ₹13.68 cr for Q1 FY27, representing an 11.5% YoY growth but a sharp 38% sequential decline from Q4 FY26. Net profit for the quarter stood at ₹1.66 cr, down significantly from ₹7.73 cr in the preceding quarter. The company has utilized only ₹1.03 cr of its ₹50 cr IPO capex budget for new IVF centers as of June 2026. Additionally, the board approved reallocating ₹1.93 cr of unspent debt repayment funds toward general corporate purposes after clearing all outstanding borrowings of ₹18.07 cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its first-quarter results post-IPO, appointed a new secretarial auditor for a five-year term, and reallocated surplus IPO funds from debt repayment to general corporate use.
ஏன் இது முக்கியம்While the company is now debt-free regarding its IPO-targeted borrowings, the sharp sequential decline in profitability and slow capex rollout are key performance indicators to watch in the medical facilities sector.
Q1 FY27 Revenue: ₹13.68 கோடிQ1 FY27 PAT: ₹1.66 கோடிIPO Capex Allocation: ₹50.00 கோடிCapex vs FY26 Revenue: ~70%Debt Repaid from IPO: ₹18.07 கோடி
📅 குறுகிய காலம்The stock may face pressure due to the 78% QoQ decline in net profit and the slow start to the expansion projects funded by the IPO.
📈 நீண்ட காலம்Long-term value depends on the successful establishment of new IVF centers using the remaining ₹48.97 cr capex budget, which represents a significant capacity increase relative to current operations.
⚠ அபாய எச்சரிக்கைகள்
Slow utilization of IPO proceeds for core expansion
Significant sequential margin contraction
High dependence on new center execution for growth
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the ₹50 cr expansion plan, as the slow initial deployment of IPO funds for new centers may delay projected revenue growth.
Gaudium IVF Q1 PAT at ₹1.66 Cr; IPO Debt Repayment of ₹18.07 Cr Completed
Gaudium IVF reported a standalone revenue of ₹13.67 cr for Q1 FY27, a sequential decline from ₹22.16 cr in Q4 FY26. Net profit fell to ₹1.66 cr compared to ₹7.73 cr in the previous quarter, primarily due to higher 'other expenses' and lower operational income. A key positive is the utilization of ₹18.07 cr from IPO proceeds to clear all outstanding debt, making the company debt-free. However, execution on the planned ₹50 cr expansion for new IVF centers is slow, with only ₹1.03 cr deployed so far.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has utilized IPO proceeds to clear its entire debt of ₹18.07 cr and reallocated a minor surplus of ₹1.92 cr to general corporate purposes.
ஏன் இது முக்கியம்While the company is now debt-free, the significant sequential drop in revenue and profit suggests operational volatility or seasonality that needs to be assessed against the long-term expansion plan.
Q1 Revenue (Standalone): ₹13.67 கோடிQ1 PAT (Standalone): ₹1.66 கோடிDebt Repaid from IPO: ₹18.07 கோடிNew IVF Center Capex Budget: ₹50.00 கோடிCapex Utilized to Date: ₹1.03 கோடிFinance Costs (QoQ Change): Down from ₹1.23 cr to ₹0.32 cr
📅 குறுகிய காலம்The market may react cautiously to the sequential decline in profitability, despite the positive news of becoming debt-free.
📈 நீண்ட காலம்Long-term value creation depends on the successful deployment of the remaining ₹48.97 cr capex for new centers to drive volume growth.
⚠ அபாய எச்சரிக்கைகள்
Slow execution of IPO-funded expansion
Significant sequential margin compression
High 'Other Expenses' relative to revenue
👀 கவனிக்க வேண்டியவை
Investors should monitor the pace of capital expenditure for new IVF centers, as the company has deployed only 2% of the allocated ₹50 cr. The transition to a debt-free balance sheet is a positive structural change to watch in upcoming interest cost savings.
19-Centre Expansion: Gaudium IVF Launches AI-Powered Signature Lab in South Delhi
Gaudium IVF has launched its first milestone centre in South Delhi, marking the start of a planned 19-centre expansion outlined in its IPO roadmap. The new facility introduces the 'Signature Lab' model, which integrates AI-powered technologies like SiD and ERICA for advanced sperm and embryo assessment. With a reported Dec 2025 quarterly revenue of ₹24.51 cr, this 19-centre rollout represents a significant scaling effort relative to its current operations. The company aims to replicate this standardized clinical model across all upcoming locations to ensure consistent success rates.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially transitioned from its IPO phase to the execution of its physical expansion strategy by opening a high-tech flagship centre.
ஏன் இது முக்கியம்This expansion is critical for scaling the business; if the 19-centre rollout is successful, it could significantly multiply the company's current revenue base of ~₹100 cr (annualized).
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as it demonstrates management's commitment to its IPO growth promises.
📈 நீண்ட காலம்If the company successfully replicates its 'Signature Lab' model across 19 centres, it could establish a dominant position in the fragmented Indian IVF market.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in managing a rapid 19-centre rollout
High competition in the premium fertility segment
Gestation period of new centres may temporarily impact margins
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline and capital expenditure for the remaining 18 centres and track the revenue ramp-up from the South Delhi facility in upcoming quarterly results.
Gaudium IVF to Start Operations at New South Extension Hub on July 16, 2026
Gaudium IVF and Women Health Limited has announced the commencement of commercial operations at its new IVF Centre/Hub in South Extension, New Delhi, effective July 16, 2026. This expansion is a direct execution of the objectives outlined in the company's IPO prospectus dated February 25, 2026. Given the company's Dec 2025 quarterly revenue of ₹24.51 cr, the addition of a new hub in a prime Delhi location represents a significant capacity increase. The facility is equipped with advanced embryology laboratories and modern medical infrastructure to provide specialized fertility services.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned its new South Extension facility from the development phase to active commercial operations.
ஏன் இது முக்கியம்This expansion increases the company's service capacity and geographic reach in a high-demand urban market, supporting its post-IPO growth strategy.
Commencement Date: ஜூலை 16, 2026Dec 2025 Quarterly Revenue: ₹24.507 கோடிDec 2025 Quarterly PAT: ₹3.6305 கோடிIPO Prospectus Date: பிப்ரவரி 25, 2026
📅 குறுகிய காலம்The announcement demonstrates timely execution of IPO promises, which is likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்The addition of new hubs is critical for scaling the business in the fragmented IVF market; successful ramp-up here could lead to further regional expansions.
⚠ அபாய எச்சரிக்கைகள்
Gestation period for the new hub to reach break-point profitability
High competition in the South Delhi healthcare market
👀 கவனிக்க வேண்டியவை
Monitor the upcoming quarterly results to assess the revenue contribution and margin impact of the new South Extension hub as it ramps up operations.
Gaudium IVF Approves ₹15 Crore Expansion for New Women Hospital in Lucknow
Gaudium IVF and Women Health Limited has approved the establishment of a new hospital in Lucknow, Uttar Pradesh, with an estimated project cost of ₹15 crore. The project will be developed through a 30-year long-term lease arrangement with a 15-year lock-in period. The company will pay 10% of net monthly revenue to the landowner, following the recovery of a ₹3 crore security deposit. This move signifies a strategic expansion into the North Indian healthcare market using an asset-light revenue-sharing model.
முக்கிய அம்சங்கள்
Estimated project cost of up to ₹15 crore for construction, medical infrastructure, and equipment.30-year lease agreement signed with a mandatory 15-year lock-in period for the Lucknow property.Revenue-sharing model established at 10% of net revenue payable to the landowner.Security deposit of ₹3 crore to be adjusted against future revenue share payments until fully recovered.The facility will be a comprehensive women's hospital managed and operated entirely by Gaudium IVF.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth step that utilizes an asset-light model to expand geographical reach. Monitor the commissioning timeline and the subsequent impact on the company's operating margins.
Gaudium IVF FY26 Update: ARPP at Rs 2.98 Lakh, Plans Expansion to 11 Hubs by FY27
Gaudium IVF reported an Average Revenue Per Patient (ARPP) of Rs. 2,97,998 for FY26, supported by 2,255 OPU procedures. The company maintains a strong clinical success rate of 58% on the first attempt, which increases to 85% for multiple attempts. Revenue is primarily driven by IVF treatments (64%) and Pharmacy sales (31%). Management has outlined a clear expansion roadmap to add 3 new hubs in FY27 and 8 additional centers in FY28 to capitalize on the 13.1% CAGR projected for the Indian IVF market.
முக்கிய அம்சங்கள்
Average Revenue Per Patient (ARPP) reached Rs. 2,97,998 with 2,255 OPU procedures completed.Revenue mix is well-diversified with IVF treatments contributing 64% and Pharmacy contributing 31%.Expansion strategy includes 3 new hubs in FY27 (Delhi/NCR and Nagpur) and 8 new centers in FY28.AI-powered tools SiD and ERICA have contributed to an 8-9% increase in clinical success rates.The company operates a network of 7 hubs and 28 spokes across 9 Indian states.
👀 கவனிக்க வேண்டியவை
Investors should track the timely execution of the FY27 hub launches as they are critical for scaling revenue. The company's focus on AI-driven clinical outcomes and high ARPP makes it a strong play in the consolidating organized IVF sector.
Gaudium IVF Q4 PAT up 29.5% to ₹8.36 Cr; FY26 Revenue crosses ₹100 Cr mark
Gaudium IVF reported a strong Q4FY26 with revenue growing 12.7% YoY to ₹30.35 Cr and PAT increasing 29.5% to ₹8.36 Cr. For the full year FY26, the company achieved a significant milestone with revenue jumping 47.6% to ₹104.35 Cr. EBITDA margins showed impressive expansion in Q4, reaching 40.1% compared to 32.4% in the previous year. The company is aggressively expanding its footprint, planning to increase its hub count from 7 to 10 in FY27 using IPO proceeds.
முக்கிய அம்சங்கள்
Q4FY26 EBITDA grew 39.6% YoY to ₹12.17 Cr with margins expanding by 771 bps to 40.1%.Full-year FY26 Revenue reached ₹104.35 Cr, a 47.6% increase over FY25's ₹70.72 Cr.Maintained a high clinical pregnancy success rate of 58% on the first IVF attempt.Announced integration of AI-led embryology platforms (SiD and ERICA) to improve outcomes.Expansion plan on track to add 19 new hubs, with 3 expected to be operational shortly.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the hub expansion plan and the impact of AI integration on success rates. The strong margin profile and debt-light balance sheet make it a compelling growth play in the specialized healthcare segment.
Gaudium IVF FY26 Net Profit Rises 19.6% to ₹22.29 Cr; Q4 Revenue Jumps 32% YoY
Gaudium IVF and Women Health Limited reported a robust performance for the fiscal year ended March 31, 2026, with annual revenue from operations growing 21.3% to ₹7,157.85 Lakhs. Net profit for the full year increased to ₹2,228.77 Lakhs from ₹1,863.38 Lakhs in FY25, reflecting steady margin maintenance. The fourth quarter was particularly strong, with revenue hitting ₹2,216.60 Lakhs, a significant 56% increase over the preceding quarter. The company's equity base expanded significantly to ₹14,926.48 Lakhs, indicating a much stronger capital position compared to the previous year.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew 21.3% YoY to ₹7,157.85 Lakhs.Net Profit for FY26 increased by 19.6% to ₹2,228.77 Lakhs compared to ₹1,863.38 Lakhs in FY25.Q4 FY26 Net Profit stood at ₹773.14 Lakhs, up 24.5% compared to ₹620.92 Lakhs in Q4 FY25.Total Equity surged to ₹14,926.48 Lakhs from ₹4,543.33 Lakhs, driven by a massive increase in 'Other Equity'.Earnings Per Share (EPS) improved to ₹3.59 for the full year from ₹3.06 in the previous fiscal.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the strong sequential growth in Q4 and healthy annual profit margins. The significant increase in the equity base suggests the company is well-positioned for future expansion or debt reduction.
NCLT Rejects Insolvency Petition Against Gaudium IVF Filed by Ramaa Capital
The Hon’ble National Company Law Tribunal (NCLT), New Delhi Bench, has dismissed an insolvency petition filed against Gaudium IVF and Women Health Limited. The petition, filed under Section 9 of the Insolvency and Bankruptcy Code (IBC) by Ramaa Capital, an operational creditor, was rejected via an order dated May 15, 2026. The company received the official copy of the order on May 22, 2026, and has confirmed that the dismissal has no adverse impact on its financial or operational activities. This resolution removes a significant legal overhang regarding the company's solvency status.
முக்கிய அம்சங்கள்
NCLT New Delhi Bench rejected the Section 9 IBC petition (C.P. (IB)/243/ND/2026) filed by Ramaa Capital.The order was passed on May 15, 2026, and officially received by the company on May 22, 2026.Management confirms there is no impact on the company's financial, operational, or other activities.The dismissal clears the company of potential Corporate Insolvency Resolution Process (CIRP) proceedings.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as it eliminates a potential legal threat to the company's operations. No further action is required, but shareholders should continue to monitor for any appeals by the creditor.
Gaudium IVF Launches India's First AI-Led Infertility Treatment via IVF 2.0 Collaboration
Gaudium IVF has introduced India's first AI-driven infertility treatment, integrating advanced embryology systems SiD and ERICA. This initiative, launched in collaboration with UK-based IVF 2.0, aims to improve fertilization and blastocyst development rates through precision sperm and embryo selection. As India's first publicly listed IVF chain, this move strengthens its competitive edge in the high-growth fertility market. The technology is expected to reduce repeat cycles, potentially lowering costs for patients while improving clinical outcomes and predictability.
முக்கிய அம்சங்கள்
First Indian IVF chain to integrate AI-led embryology systems SiD and ERICA into routine clinical practice.Strategic collaboration with UK-headquartered IVF 2.0 to bring globally advanced embryology intelligence to India.SiD technology optimizes sperm selection while ERICA provides data-driven ranking of embryos to improve success rates.The move comes just one month after the company became India's first publicly listed IVF chain.Aims to reduce the need for repeat cycles, lowering the financial and emotional burden on patients.
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of these AI services and their impact on the company's clinical success rates and margins. This technological leadership could differentiate Gaudium in a fragmented market and drive higher patient volumes.
Gaudium IVF and Women Health Limited has been served with an arbitration petition by Neomile Corporate Advisory Limited in the Bombay High Court. The claimant is seeking interim measures for a payment of ₹29,20,50,000 (including GST) for alleged advisory services related to the company's IPO. Gaudium IVF has formally contested the claim, describing it as frivolous, unsubstantiated, and based on factual misstatements. The company is currently taking legal steps to safeguard its interests against this significant financial claim.
முக்கிய அம்சங்கள்
Arbitration petition filed under Section 9 of the Arbitration & Conciliation Act, 1996.Total claim amount involved is ₹29,20,50,000 inclusive of GST.Dispute relates to alleged advisory services provided during the company's Initial Public Offering (IPO).Matter is currently pending before the High Court of Judicature at Bombay.Company management has officially labeled the petition as frivolous and contrary to evidence.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of this litigation as an adverse ruling could result in a significant cash outflow of over ₹29 crore. While the company is defending the case, this represents a contingent liability that may impact short-term sentiment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
